CK19、HBME-1、CD56、BRAF V600E、FAM210B在甲状腺乳头状结构诊断中的应用

Application of CK19,HBME-1,CD56,BRAF V600E,FAM210B in diagnosis of thyroid with papillary structure

目的探讨CK19、HBME-1、CD56、BRAF V600E和FAM210B蛋白表达在甲状腺乳头状结构诊断中的作用及FAM210B和BRAF V600E与甲状腺乳头状癌临床病理特征的关系。方法连续收集2017年1月—2020年9月××省第二人民医院PTC患者的病理标本279例,甲状腺乳头状增生标本85例。用免疫组化SP法检测甲状腺乳头状癌(papillary thyroid carcinoma,PTC)和甲状腺乳头状增生中CK19、HBME-1、CD56、BRAF V600E和FAM210B的表达情况,分析FAM210B和BRAF V600E在不同临床病理特征的PTC组织中的表达情况。结果CD56在PTC组织中表达率为10.03%,在甲状腺乳头状增生中表达率为94.12%;CK19、HBME-1、BRAF V600E、FAM210B在PTC组织中的阳性率均高于甲状腺乳头状增生,差异有统计学意义(P<0.01);FAM210B表达与年龄、肿块大小和淋巴结转移情况具有相关性,BRAF V600E表达与性别、年龄、肿块大小和淋巴结转移情况具有相关性,差异有统计学意义(P<0.01)。结论CK19、HBME-1、FAM210B、BRAF V600E联合CD56标记有助于PTC的诊断和鉴别诊断;检测FAM210B和BRAF V600E有助于评估肿瘤的生物学行为及预后,对指导治疗和提高疗效有重要意义。

Objective To explore the role of CK19,HBME-1,CD56,BRAF V600E and FAM210B protein expression in the diagnosis of thyroid with papillary structure,and to investigate the relationship between the expression of FAM210B,BRAF V600E and clinical features of papillary thyroid carcinoma(PTC).Methods 279 pathological specimens of PTC patients from the Second People's Hospital of Anhui Province from January 2017 to September 2020 were continuously collected,and 85 specimens of thyroid papillary hyperplasia were collected.Immunohistochemical SP method was used to detect the expressions of CK19,HBME-1,CD56,BRAF V600E,FAM210B in PTC and papillary thyroid hyperplasia specimens.The expression of BRAF V600E and FAM210B in PTH tissues of clinicopathologic feature was analyzed.Results The expression rate of CD56 was 10.03%in PTC and 94.12%in thyroid papillary hyperplasia.The positive rates of CK19,HBME-1,BRAF V600E and FAM210B in PTC were higher than those in thyroid papillary hyperplasia,the difference were statistically significant(P<0.01).The expressions of FAM210B had significant correlation with the clinical features of PTH such as age,size of lump,and lymph-node metastasis.The expressions of BRAF V600E had significant correlation with the clinical features of PTH such as gender,age,size of lump,and lymph-node metastasis.Conclusions The combined detection of CK19,HBME-1,FAM210B,BRAF V600E and CD56 can be useful biomarkers for the diagnosis and differential diagnosis of PTC.The detection of FAM210B and BRAF V600E has positive effects on estimating the biological behavior and prognosis of PTC,and it is of great significance to guide treatment and improve curative effect.